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Francisella tularensis causes tularemia and is a potential biothreat. Given the limited antibiotics for treating tularemia and the
possible use of antibiotic-resistant strains as a biowarfare agent, new antibacterial agents are needed. AR-12 is an FDA-approved
investigational new drug (IND) compound that induces autophagy and has shown host-directed, broad-spectrum activity in
vitro against Salmonella enterica serovar Typhimurium and F. tularensis. We have shown that AR-12 encapsulated within aceta-
lated dextran (Ace-DEX) microparticles (AR-12/MPs) significantly reduces host cell cytotoxicity compared to that with free AR-
12, while retaining the ability to control S. Typhimuriumwithin infected humanmacrophages. In the present study, the toxicity
and efficacy of AR-12/MPs in controlling virulent type A F. tularensis SchuS4 infection were examined in vitro and in vivo. No
significant toxicity of blankMPs or AR-12/MPs was observed in lung histology sections when the formulations were given intra-
nasally to uninfected mice. In histology sections from the lungs of intranasally infected mice treated with the formulations, in-
creased macrophage infiltration was observed for AR-12/MPs, with or without suboptimal gentamicin treatment, but not for
blank MPs, soluble AR-12, or suboptimal gentamicin alone. AR-12/MPs dramatically reduced the burden of F. tularensis in in-
fected humanmacrophages, in a manner similar to that of free AR-12. However, in vivo, AR-12/MPs significantly enhanced the
survival of F. tularensis SchuS4-infected mice compared to that seen with free AR-12. In combination with suboptimal gentami-
cin treatment, AR-12/MPs further improved the survival of F. tularensis SchuS4-infected mice. These studies provide support
for Ace-DEX-encapsulated AR-12 as a promising new therapeutic agent for tularemia.
Francisella tularensis, which causes the life-threatening diseasetularemia in humans and animals, is one of themost infectious
bacterial pathogens known (1). Four different subspecies of Fran-
cisella have been classified: F. tularensis subsp. tularensis (type A),
F. tularensis subsp. holarctica (type B), F. tularensis subsp. novi-
cida, and F. tularensis subsp. mediasiatica. Among the four sub-
species, F. tularensis subsp. tularensis (type A) is the most virulent
in humans and is found largely throughout North America and in
some parts of Europe (1). Disease caused by the other three sub-
species is limited primarily to immunocompromised individuals.
The F. tularensis SchuS4 (type A prototype) strain has an infec-
tious dose of fewer than 25 bacteria and a mortality rate of 30 to
60% for untreated pneumonic infections (2, 3). Tularemia is con-
sidered to be a reemerging disease, with recent outbreaks reported
worldwide, including in the United States (4, 5). Because of the
ease of aerosol transmission, F. tularensis could be transmitted
deliberately, resulting in substantial morbidity and mortality on a
large scale. It has therefore been recognized as a potential biolog-
ical warfare agent and is classified in tier 1, the highest-level tier for
bioterrorism agents classified by theU.S. Centers forDisease Con-
trol and Prevention (CDC) (1, 3).
Although a live attenuated vaccine strain (LVS) of F. tularensis
has been used in humans (6), there is no currently licensed U.S.
vaccine. Moreover, antibiotic treatment of tularemia is limited to
aminoglycosides, fluoroquinolones (e.g., ciprofloxacin), and tet-
racyclines (7). At present, there is no naturally acquired resistance
to these antibiotics in human/environmental isolates of F. tular-
ensis (8). However, constant exposure of this bacterium to in-
creasing concentrations of ciprofloxacin in vitro can select for re-
sistant strains, including those cross-resistant to other clinically
relevant antibiotics, including other fluoroquinolones and amin-
oglycosides (9). Additionally, subspecies of F. tularensis have dif-
ferent antibiotic sensitivities, making treatment more compli-
cated (10). Even with antibiotic treatment, many therapeutic
failures and relapses have been reported (11, 12). Given these is-
sues, the development of new antibacterial agents with novel
mechanisms of action against F. tularensis has become a priority.
Indeed, novel therapeutic approaches have been explored in re-
cent years (7), including the use of newer antibiotics (e.g., tigecy-
cline, ketolides, and fluoroquinolones), improving antibiotic de-
livery in vivo (e.g., liposome delivery), enhancement of the innate
immune response by use of antimicrobial peptides, and combina-
torial approaches with conventional antibiotics and immune ad-
juvants (7, 13).
F. tularensis is difficult to treat because it is a facultative intra-
cellular bacterium that targetsmacrophages andhas severalmech-
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anisms that enable it to evade immune clearance. Upon host cell
entry, the bacterium affects signaling cascades to limit host pro-
tective inflammatory responses, block fusion of Francisella-con-
taining phagosomeswith lysosomes, and escape into the cytosol to
proliferate, which results in host cell death (14–19). Several hours
after entry into the cytoplasm, subsets of wild-type Francisella or-
ganisms and bacterial mutants that are incapable of escaping from
phagosomes have been observed in double-membrane vacuoles
with markers of autophagosomes (20, 21). The relative impor-
tance of autophagy in controlling Francisella infection in macro-
phages remains uncertain, depending on themacrophage cell type
and the bacterial strain. Evidence exists for Francisella escape from
autophagy mechanisms and for ATG5-independent autophagy
increasing F. tularensis survival (22, 23).
One agent that has been shown to promote autophagy is AR-
12. AR-12 (also known as OSU-03012; Arno Therapeutics) is an
approved derivative (as an investigational new drug [IND]) of
celecoxib that lacks cyclooxygenase-2 (COX-2) inhibitor activity.
It has been investigated as an anticancer agent that suppresses
tumor cell viability through multiple mechanisms, including the
induction of autophagy (24–26). We have shown that AR-12 en-
hances the clearance of the intracellular bacterial pathogens Sal-
monella and Francisella from infectedmacrophages specifically via
induction of autophagy (27–29). The effect of AR-12 on control of
Francisella was fully reversed in the presence of the autophagy
inhibitor 3-ME or the lysosomal inhibitor chloroquine (27). Ini-
tially, it was thought that the mechanism of action of AR-12 was
the direct inhibition of PDK-I (30), which results in lower AKT
phosphorylation, along with endoplasmic reticulum stress and
autophagy induction (24, 26, 31). However, recent studies indi-
cate that PDK-I is not the target of AR-12 (26, 32); rather, the
target is immunoglobulin heavy chain-binding protein (GRP78/
BiP). Additionally, our previous studies indicated that AR-12 in-
duces autophagy inmacrophages at 1M(28, 29), which is much
lower than the concentration observed for its inhibitory activity
against PDK-1. Thus, although the exactmechanismof autophagy
induction has not been resolved, the pathogen clearance mecha-
nism of AR-12 is uniquely at the drug-host instead of drug-patho-
gen interface, limiting the possibility of cultivating resistant
pathogens. Unfortunately, due to toxicity and hydrophobicity
concerns, AR-12 is unable to reach therapeutic doses in vivo,
which significantly limits its use.
We recently showed that encapsulation of AR-12 in acetalated
dextran (Ace-DEX) microparticles (AR-12/MPs) dramatically re-
duces cytotoxicity while retaining the ability to enhance Salmo-
nella clearance via autophagy in human monocyte-derived mac-
rophages (hMDMs) (29). Ace-DEX is derived from Food and
Drug Administration (FDA)-approved dextran and is an acid-
sensitive polymer that is stable at neutral pH but will degrade
rapidly upon introduction to an acidic environment, such as that
in the phagolysosome (33). This is important for treatment of F.
tularensis infection because Ace-DEX MPs can passively target
phagocytes, and other cell types are unable to engulf particles of
that size. Once the particles are internalized, they rapidly release
their cargo. In this study, we evaluated the ability of AR-12/MPs to
control Francisella infection in hMDMs and in the mouse model
of tularemia. Also, we evaluated the in vivo toxicity of intranasally
(i.n.) delivered formulations by evaluating histology sections of
uninfected and infected lungs. Our studies shed light on the ability
of AR-12/MPs to treat tularemia through both needled and nee-
dle-free routes.
MATERIALS AND METHODS
Formulation of AR-12/MPs. Free base AR-12 was kindly provided by
Arno Therapeutics, Inc. Encapsulation of AR-12-encapsulated Ace-DEX
microparticles (AR-12/MPs) was performed as described in our previous
publication (29). In brief, 1 day prior to particle formation, all glassware
was soaked in 1 M sodium hydroxide overnight. The glassware was
washed with purified water by use of a Milli-Q Integral water purification
system (Billerica, MA) and then dried directly before use. One hundred
milligrams of Ace-DEX polymer and 2 mg of AR-12 (2% [wt/wt] loading
concentration) were dissolved in dichloromethane (DCM). The DCM-
containing polymer and drug were added to 3% (wt/wt) polyvinyl alcohol
(PVA) in phosphate-buffered saline (PBS; pH 7.4) to create a stabilized
emulsion. The emulsion was then partially submerged in an ice bath and
sonicated using aMisonix ultrasonic liquid processor (Farmingdale, NY).
Following sonication, the solution was poured into a 0.3% PVA solution
in PBS and stirred for 2 h to allow for particles to harden. Following
particle hardening, unencapsulated drug was removed using a sterile
MidiKros tangential-flow filtration system (Spectrum Labs, Rancho
Dominguez, CA). The particles were then collected, frozen, and lyoph-
ilized, yielding a white powder. The endotoxin concentration in the
particle preparations was shown to be 0.1 endotoxin unit (EU)/
ml/mg of MPs.
Size, imaging, and encapsulation efficiency ofAR-12/MPs.Endotoxin-
free AR-12/MPs were prepared as previously described (29). Particle size
was determined using a model 370 Nicomp submicrometer particle sizer
(Santa Barbara, CA). Briefly, particles were suspended in basic water to a
concentration of 0.1 mg/ml and were added to the particle sizer. Samples
were diluted with basic water until the count rate was acceptable for the
instrument. The average diameter was derived from three separate runs.
Images of AR-12/MPs were acquired using an FEI Nova NanoSEM 400
microscope. MPs were suspended in basic water to a concentration of 10
mg/ml, and 15 l was placed on a scanning electron microscopy (SEM)
stub and allowed to air dry. The stub was then further processed and
imaged to analyze particle morphology. The encapsulation efficiency of
AR-12/MPs was defined as the percentage of AR-12 retained within theMPs
with respect to the initial drug load. The encapsulation efficiency of AR-12/
MPs was determined by preparing a 1-mg/ml solution of AR-12/MPs and
blankMPs in dimethyl sulfoxide (DMSO). The samples were then read on a
plate reader at an excitation wavelength of 280 nm and an emission wave-
length of 380 nm and compared to a standard curve for free AR-12.
Isolation of hMDMs. hMDMs were isolated from blood obtained
from healthy human donors via venipuncture (34) following a protocol
approved by the Ohio State University and University of North Carolina
Institutional Review Boards. Written informed consent was provided by
study participants. Briefly, peripheral blood mononuclear cells (PBMCs)
were isolated from heparinized blood over a Ficoll cushion (GE Health-
care Bioscience, Piscataway, NJ). PBMCs were then cultured in sterile
screw-cap Teflon wells in RPMI 1640 plus L-glutamine (Gibco-Life Tech-
nologies, Grand Island, NY) with 20% autologous human serum at 37°C
in a humidified incubator containing 5% CO2 for 5 days. PBMCs were
then recovered fromTeflonwells by chilling the cells on ice, resuspending
them in RPMI 1640 with 10% autologous serum, and allowing them to
attach in 6-well or 24-well tissue culture plates for 2 to 3 h at 37°C in a
humidified incubator containing 5% CO2. Lymphocytes were then
washed away, leaving hMDM monolayers at a density of approximately
2.0 105 cells/well for 24-well plates for F. tularensis SchuS4 infection.
Bacterial cultures and analysis of bacterial growth in hMDMs. The
F. tularensis SchuS4 strain (type A) used in this study was described pre-
viously (15). Bacteria were cultured on chocolate II agar plates (Becton
Dickinson, Sparks, MD) for 48 h at 37°C prior to use for all experiments.
Experiments involving the F. tularensis SchuS4 strain were carried out in
The Ohio State University biosafety level 3 (BSL3) select-agent facility in
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accordance with CDC and locally approved BSL3 facility and safety stan-
dards. Analysis of bacterial growth in hMDMs was described previously
(27). Briefly, F. tularensis SchuS4 was grown on chocolate II agar plates at
37°C for 48 h. Bacteria were suspended in PBS to an optical density at 600
nm (OD600) of 0.4, equivalent to 3 10
9 CFU/ml. hMDMs were infected
with SchuS4 at a multiplicity of infection (MOI) of 50 in the presence of
2% autologous serum in RPMI 1640 plus L-glutamine (Gibco-Life Tech-
nologies, Grand Island, NY). Two hours after infection, extracellular bac-
teria were removed by addition of 50 g/ml of gentamicin (Gibco-Life
Technologies, Grand Island, NY) to the culture medium for 1 h, and then
the cell monolayer was washed thoroughly three times with prewarmed
RPMI 1640 to remove unattached bacteria. Infected hMDMs were then
treated with different concentrations of free AR-12 or AR-12/MPs, as well
as controls, in fresh culturemediumcontaining 2%autologous serumand
gentamicin at 10 g/ml to eliminate potential reinfection by extracellular
bacteria. Soluble AR-12 was dissolved at 10 mg/ml in DMSO and diluted
to the appropriate concentrations in RPMI 1640 containing 2% autolo-
gous serum. At 22 h posttreatment, the infected cells were lysed with 0.1%
Triton X-100 (Calbiochem, San Diego, CA) in PBS for 15 min. The cell
lysates were then serially diluted with PBS and spread on chocolate II agar
plates. The numbers of surviving intracellular bacteria were determined
by enumerating CFU after 72 h of incubation at 37°C.
Mice. Pathogen-free 6- to 8-week-old female BALB/c mice were pur-
chased from Harlan Sprague. Mice were provided food and water ad libi-
tum, divided into groups in sterile microisolator cages, and allowed to
acclimatize for 2 to 3 days before challenge. All experimental procedures
were carried out in strict accordance with guidelines established by The
Ohio State University and University of North Carolina Institutional An-
imal Care and Use Committees (IACUCs), and all efforts were made to
minimize animal suffering.
Toxicity study of AR-12/MPs in vivo. To examine the toxicity of
AR-12/MPs in mice, mice were administered free AR-12 or AR-12/MPs
either intranasally (i.n.) or intraperitoneally (i.p.) for two consecutive
days. For i.n. delivery of the drug, mice were anesthetized i.p. with 200 l
tribromoethanol anesthesia (2.5mg 2,2,2-tribromoethanol, 5ml 2-meth-
yl-2 butanol, 200 ml water) or 1.5 mg ketamine/kg of body weight in 200
l PBS and then treated with different doses (1.5, 0.75, and 0.325 mg/kg)
of free AR-12 or AR-12/MPs daily for 2 days. Free AR-12 was dissolved in
50 l of polyethylene glycol 400 (PEG 400)-0.9% saline-ethanol (50:35:
15), while AR-12/MPs were suspended in 50 l PBS. Mice in the control
groups received PBS, PEG-saline-ethanol, or blank MPs equivalent in
mass to 1.5mg/kg AR-12/MPs. For the i.n. delivery of the drug, mice were
given 5, 2.5, or 1.25 mg/kg of free AR-12 or AR-12/MPs daily for 2 days in
200 l of PEG-saline-ethanol or PBS, respectively. Mice in the control
groups received PBS or blank MPs equivalent in volume to 200 l of
PEG-saline-ethanol or in mass to 5 mg/kg AR-12/MPs, respectively. The
experimental animals were observed daily throughout the course of study
for body weight, clinical signs, and mortality. At the end of the experi-
ment, mice were sacrificed, and lungs were collected, fixed in 4% parafor-
maldehyde, and subsequently subjected to histopathological examination
following hematoxylin and eosin (H&E) staining, which was performed
by the Comparative Pathology and Mouse Phenotyping Facility of the
College of Veterinary Medicine, The Ohio State University.
Mouse infection with F. tularensis SchuS4. F. tularensis SchuS4 was
grown on chocolate II agar plates for 48 h at 37°C. The bacteria were
collected, suspended in PBS, and adjusted to an OD600 of 0.4, equivalent
to 3  109 CFU/ml. The desired concentrations of F. tularensis SchuS4
were prepared by serial dilution. Mice were infected with F. tularensis
SchuS4 i.n. or i.p., with a lethal dose of 10 CFUpermouse in 50l PBS for
i.n. infection or in 100 l PBS for i.p. infection. For i.n. infection and
dosing,micewere anesthetizedwith 200l tribromoethanol anesthesia or
1.5 mg/kg ketamine as described above.
Evaluation of protective efficacy of AR-12/MPs in F. tularensis
SchuS4-infected BALB/c mice. To evaluate AR-12 as a treatment for F.
tularensis SchuS4 infection, we codeliveredAR-12/MPswith a suboptimal
daily dose of gentamicin (0.7mg/kg for i.p. infection and 0.5mg/kg for i.n.
infection), which was determined prior to the experiment (see Fig. S1 in
the supplemental material). After determining the maximum tolerated
dose of AR-12/MPs for each route (10 mg/kg i.p. and 3 mg/kg i.n.), we
infectedmice with F. tularensis SchuS4 and delivered AR-12/MPs through
the same needled or needle-free route. The infected mice were given AR-
12/MPs two (days 0 and 1) or three (days 0, 1, and 2) times postinfection,
and gentamicinwas given i.p. daily. The infectedmice weremonitored for
survival for up to 2 weeks postinfection.
Determination of bacterial burdens in the lungs and spleens of in-
fected mice. To examine the effects of AR-12/MP treatment following F.
tularensis SchuS4 infection in the mouse model, mice were infected i.n. as
described above for the protective efficacy study. A suboptimal dose of
gentamicin (0.5 mg/kg for i.n. infection) was given i.p. daily. The infected
mice were monitored for survival and/or sacrificed at the indicated time
points postinfection. Bacterial burdens in the lungs and spleens of in-
fected mice were determined by tissue homogenization and plating for
CFU enumeration.
Statistical analysis. Data are presented as means  standard devia-
tions (SD). P values were calculated using one-way analysis of variance
(ANOVA) for multiple comparisons and adjusted with Bonferroni’s cor-
rection. The chi-square test was used for survival analysis. Statistical anal-
ysis was performed using GraphPad Prism 5 or Microsoft Office Excel
2010.
RESULTS
AR-12/MP characteristics. AR-12/MPs were 265 41 nm as de-
termined by use of a submicrometer particle sizer, and the encap-
sulation efficiencywas 36%, yielding anAR-12 final weight load in
particles of 0.72% (wt/wt). The spherical morphology of AR-12/
MPs was conserved relative to that in our previous work (Fig. 1),
and the size of the MPs aligned with our submicrometer particle
sizer measurements (29).
AR-12 treatment of F. tularensis SchuS4-infected hMDMs in
vitro.To examinewhether AR-12/MPs are capable of inhibiting F.
tularensis SchuS4 growth in macrophages, hMDMs were infected
with F. tularensis SchuS4 for 2 h, washed, and treated with various
concentrations of free AR-12 or AR-12/MPs (1.25, 2.5, and 5M)
for 22 h. AR-12/MPs inhibited F. tularensis SchuS4 growth in
FIG 1 Scanning electron micrograph showing microparticles of acetalated
dextran encapsulating AR-12.
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hMDMs in a dose-dependent manner, similarly to free AR-12, re-
sulting in a 2-log decrease in CFU (Fig. 2). Although AR-12/MP
treatment did not increase the clearance of F. tularensis SchuS4 in
hMDMs compared to that with free drug, AR-12/MPs signifi-
cantly reduced the cytotoxicity to macrophages compared to that
with free drug, allowing for higher concentrations to be used (29).
Evaluation of toxicity in mice following AR-12 administra-
tion. To evaluate the in vivo toxicity of the AR-12 formulations
with i.n. delivery, mice were given AR-12/MPs or free AR-12 at
1.5, 0.75, or 0.325mg/kg daily for 2 days. The control groups were
treatedwith PBSor blank particles (1.5mg/kg), also given daily for
2 days. The treated mice were monitored for clinical signs of tox-
icity, and at 10 days posttreatment, lungs were collected and ex-
amined for histopathology. Delivery of AR-12/MPs resulted in no
adverse clinical signs and only a mild increase in immune cell
migration into the lung tissue compared to that in the untreated
animals (Fig. 3). Delivery of 1.5 mg or 0.75 mg free AR-12 i.n.
resulted in clinical illness shortly after administration of the drug,
followed by recovery, which was not observed with AR-12/MPs.
For i.p. delivery of the drug, mice were treated daily with AR-12/
MPs or free AR-12 at 5, 2.5, or 1.25 mg/kg for 2 days, and no
abnormal clinical signs (e.g., sickness or weight loss) were noticed
after 10 days posttreatment for any group (data not shown). These
results indicate that the i.n. and i.p. routes for delivery of AR-12/
MPs are well tolerated in mice at these dosages.
AR-12 treatment of F. tularensis SchuS4-infected mice.
AR-12 or AR-12/MPs were delivered alone or codelivered with a
suboptimal daily dose of gentamicin, which was determined pre-
viously (0.7 mg/kg or 0.5mg/kg given daily for i.p. or i.n. delivery,
respectively) (see Fig. S1 in the supplemental material). In addi-
tion, we examined the effectiveness of delivering AR-12 or AR-12/
MPs via the same route (i.p. or i.n.) as that used for the bacterial
infection. For all treatment routes, we achieved significantly
greater survival with treatment groups than with untreated
groups. Infection and treatment (both i.p.) with 1.5 mg/kg (Fig.
4A) or 3 mg/kg (Fig. 4B) of free AR-12 codelivered with daily
suboptimal gentamicin increased the survival time compared to
that with gentamicin alone, but the improvement was not statis-
tically significant. However, treatment with 1.5mg/kg (Fig. 4A) or
3 mg/kg (Fig. 4B) of AR-12/MPs codelivered with suboptimal
gentamicin resulted in significantly greater protection than that
FIG 2 Intracellular survival of F. tularensis SchuS4 in hMDMs following
AR-12 administration. hMDMs were infected (MOI  50) for 2 h, washed
with gentamicin, and treatedwith free or encapsulated AR-12. The numbers of
intracellular bacterial CFU were determined by plating cell lysates at 22 h
postinfection. Negative-control groups included medium alone (Med), blank
particles (MPs), and (0.05% [vol/vol]) DMSO (free AR-12 diluent). AR-12,
unencapsulated drug; AR-12/MPs, Ace-DEX-encapsulated AR-12; MPs,
empty Ace-DEXmicroparticles. The experimentwas repeated three times, and
the data from a representative experiment are presented as averages  stan-
dard deviations (SD) (*, P 0.05; **, P 0.01; ***, P 0.001).
FIG 3 Lung histology following AR-12 administration. Low (top;100)- and high (bottom;200)-magnification lung histology sections are shown for mice
that received PBS (A), free AR-12 (B), blankMPs (C), or AR-12/MPs (D) via the i.n. route. Immune cell infiltration (macrophages are indicated by arrows) was
minimal to mild for blank MPs (C) and mild to moderate for AR-12/MPs (D). Tissue samples were taken 10 days after dosing. For each sample, 1.5 mg/kg was
given at days 0 and 1, and for blank MPs, comparable weights of particles were given. T, terminal bronchiole.
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with either gentamicin or AR-12/MPs alone (P  0.02). AR-12
alone did not show a protective effect in infected mice when both
bacteria and AR-12 were delivered by the i.n. route (Fig. 5A).
However, codelivery of the lowest concentration of free AR-12
(0.325 mg/kg) with suboptimal gentamicin resulted in greater
protection than that with either daily gentamicin or free AR-12
alone (Fig. 5B) (P 0.02). Importantly, treatment with 1.5mg/kg
of AR-12/MPs alone by the i.n. route increased the survival time
by 2 or 3 days compared to that for the free AR-12-, PBS-, or blank
particle-treated group (Fig. 5C). When AR-12/MPs were codeliv-
ered with daily gentamicin, all encapsulated AR-12 doses signifi-
cantly protected the mice, with 1.5 mg/kg and suboptimal genta-
micin resulting in 100% protection (P 0.01) (Fig. 5D).
Because i.n. delivery of 1.5 mg/kg of AR-12/MPs with daily
suboptimal gentamicin was 100% protective and significantly
more protective than eitherAR-12/MPs or the antibiotic alone, we
increased the number ofmice studied at this dose and used similar
doses of free and encapsulated AR-12 without gentamicin. This
result replicated the significant difference versus the components
used individually as treatments but protected at 80%, in contrast
to the 100% protection (P 0.01) that was observed in the previ-
ous trial (Fig. 5E).
A histopathological study of lung sections from mice from
the experiment described for Fig. 5E revealed increased inflam-
mation in the lungs of AR-12/MP-treated mice compared to
those of mice treated with blank MPs, free AR-12, or gentami-
cin alone at both days 3 and 6 postinfection. This was mani-
fested by the presence of perivascular and peribronchiolar cells
composed of foamy alveolar macrophages, macrophages, and
neutrophils (Fig. 6, lower panel). However, at day 9 postinfec-
tion, the condition resolved and there was no difference in the
inflammation scores for the lungs from gentamicin- versus AR-
12/MP-plus-gentamicin-treated mice (Fig. 5C).
In addition to survival and lung histopathology studies, we
evaluated the numbers of CFU in the lungs and spleens of mice at
days 3, 6, and 9 postinfection for the experiment described for Fig.
5E. As shown in Fig. 7, there was no significant decrease in the
number of CFU recovered at days 3 and 6 postinfection for mice
treated with free AR-12 alone versus controls after two adminis-
trations of drug. Also, the addition of daily gentamicin to free
AR-12 did not result in significant reductions in the number of
CFU recovered beyond that observed with gentamicin alone. In
contrast, there was a significant reduction in the number of
CFU with AR-12/MPs alone versus free AR-12. AR-12/MPs in
combination with daily suboptimal gentamicin showed further
reductions in CFU compared to the numbers with gentamicin
alone, although the results did not reach statistical significance.
By day 9 postinfection, the results for free AR-12 and AR-12/
MPs in combination with gentamicin were similar, with both
reducing the numbers of CFU in organs more than gentamicin
alone.
Increased AR-12 dosing of F. tularensis SchuS4-infected
mice. Finally, we sought to determine if increasing the number of
doses (from 2 to 3 daily doses) resulted in better protection. Dos-
ing twice (days 0 and 1) with AR-12/MPs alone resulted in 0%
survival, whereas an additional dose on day 2 resulted in 80%
survival of infectedmice, which was significantly better than what
was seenwith suboptimal gentamicin alone orwith blank particles
(Fig. 8A). Treatment with AR-12/MPs and gentamicin also re-
sulted in 80% survival, similar to earlier experiments (Fig. 5D).
Bacterial burdens were also assessed in the lungs and spleens of
these mice at days 3 and 6 postinfection. Although AR-12/MP or
gentamicin treatment alone at these time points clearly reduced
bacterial burdens in the lungs, neither resulted in a statistically
significant difference versus mice treated with blank MPs. How-
ever, the combination of AR-12/MPs with gentamicin signifi-
cantly decreased bacterial burdens in the lungs and spleens com-
pared to those in mice treated with AR-12/MPs or gentamicin
alone at day 6 postinfection (P 0.02) (Fig. 8B).
DISCUSSION
Infections due to intracellular bacterial pathogens, including F.
tularensis, are particularly difficult to treat. Treatment of tulare-
mia in humans is confined to few antibiotics, including aminogly-
cosides (particularly streptomycin and gentamicin) with known
toxicities at therapeutic doses (7, 35). Even with antibiotic treat-
ment, high failure and/or relapse rates (up to 33%) have been
reported (35). Resistance of this pathogen to conventional antibi-
FIG 4 Survival curves for BALB/c mice (n 5) infected i.p. with 10 CFU of F. tularensis SchuS4 following AR-12 treatment. The infected mice were given 1.5
or 3 mg/kg of AR-12 or AR-12/MPs i.p. at days 0 and 1 postinfection, with or without 0.7 mg/kg daily gentamicin i.p. for the length of the experiment. * and **,
statistical significance with respect to the PBS control and blank MP-treated groups (*, P 0.05; **, P 0.02);, statistical significance with respect to 1.5 mg
AR-12/MPs (P 0.05).
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otic therapy has not been reported (8); however, in the context of
a biological weapon of terror, antibiotic-resistant strains could be
created and pose a significant public health threat. Therefore,
there is substantial interest from a public healthmanagement per-
spective in developing new antimicrobial strategies to control this
bacterial pathogen (7).
AR-12 has previously been used to enhance the clearance of
several intracellular pathogens; however, its hydrophobicity and
toxicity limit the in vivo therapeutic efficacy. To overcome the
hydrophobic/toxic drawbacks and also to passively target infected
macrophages, we encapsulated AR-12 in the acid-sensitive poly-
mer Ace-DEX. The AR-12/MPs used in this study showed an en-
capsulation efficiency similar to that in our previous work (29)
and were shown to be 265 nm in diameter (Fig. 1), which is an
ideal size for uptake via macrophages but not by nonphagocytic
cells (36–38). Particle formulation through sonication generates a
polydispersed particle population; however, Champion et al.
noted that the main determinant for uptake by macrophages is
shape, and thus, polydispersed particle populations of the same
shape that lie within the optimal uptake range for macrophages
should be taken up at similar rates (38). Additionally, particles of
this size are not optimal targets for dendritic cells and will not be
trafficked away from the site of administration as readily, allowing
for persistent passive targeting ofmacrophages (39). The potential
for sustained passive treatment at the site of administration is
important for an intracellular bacterium such as F. tularensis,
FIG 5 Survival curves for BALB/c mice (n 5) infected i.n. with 10 CFU of F. tularensis SchuS4 following AR-12 treatment. The infected mice were given free
AR-12 (A), free AR-12 with gentamicin (Gent) (B), AR-12/MPs (C), or AR-12/MPs with Gent (D). Free AR-12 and AR-12/MPs were given i.n. at 0.325, 0.75, or
1.5 mg/kg on days 0 and 1 postinfection. As indicated, gentamicin was given i.p. daily at 0.5 mg/kg for the length of the study. (E) In a separate experiment, the
survival curves for BALB/cmice infected i.n. with 10 CFU of F. tularensis SchuS4 were determined. The infectedmice were given 1.5mg/kg of AR-12/MPs i.n. on
days 0 and 1 postinfection. Gentamicin was given daily at 0.5 mg/kg via the i.p. route for the length of the study. * and **, statistical significance with respect to
the blank MP control group (*, P 0.05; **, P 0.02).
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which uses various strategies to avoid recognition by the host and
allow for its replication and dissemination (14, 15, 19).
In the current study, we observed a dose-dependent inhibitory
effect of AR-12/MPs on the growth of F. tularensis in hMDMs that
was comparable to that of free drug (Fig. 2), which occurs at con-
centrations of drug that do not directly kill F. tularensis in vitro
(27). However, in our previous work with AR-12/MPs, we dem-
onstrated that encapsulation allowed for higher drug concentra-
tions to be used, as theMPs alleviated the in vitro toxicity observed
with free drug at concentrations of 5 M (29). Our collective
data provide further evidence for the effectiveness of AR-12/MPs
in controlling intracellular bacterial pathogens that reside inmac-
rophages. In fact, the increasing evidence for AR-12’s effectiveness
in controlling intracellular pathogens, such as Francisella and Sal-
monella (40, 41), indicates the potential of AR-12 as a broad-spec-
trum, host-directed anti-infective agent.
We examined the toxicity of AR-12/MPs by using a mouse
model. Lung histopathological studies of i.n. AR-12/MP-treated
mice (uninfected) showed a small increase in infiltration of im-
mune cells compared to that in PBS-treated control mice (Fig. 3).
AR-12 and AR-12/MPs administered i.n. to infectedmice showed
an inflammation score of 3 at 6 days postinfection (Fig. 7). This
score indicates that there is a greater inflammatory response
when AR-12 is administered to an infected mouse than an un-
infected mouse and highlights the potential benefit of using
AR-12 in a manner similar to that for many adjunctive immu-
nomodulatory compounds. However, in contrast to several of
these compounds, such as Toll-like receptor (TLR) agonists
(42), AR-12/MPs do not appear to have significant toxicities,
even when the host is not infected. A more comprehensive
evaluation of the potential adverse effects of the drug in vivo is
planned for future experiments.
AR-12/MPs appeared to work as efficiently in vitro as free
AR-12 at concentrations below those of free AR-12 that cause
toxicity, consistent with our previous work (29). In vitro, the ben-
efits of encapsulation, i.e., enhanced macrophage targeting and
elimination of free compound hydrophobicity, are not as promi-
nent. Additionally, at the concentrations used, we were likely sat-
urating the ability to induce autophagy regardless of the encapsu-
lation status. However, we demonstrated here that passive
FIG 6 Histology of lung sections taken from mice infected i.n. with 10 CFU of F. tularensis and then treated with 1.5 mg of AR-12/MPs on days 0 and 1
postinfection, with or without a suboptimal daily dose (0.5 mg/kg) of gentamicin i.p. for the duration of the experiment. Low-magnification (top; 10) and
high-magnification (bottom;200) images are provided. Inflammationwas scored blindly by a pathologist, according to a tiered, semiquantitative scale adopted
from the work of Slight et al. (47), as follows: 0  no inflammation, 1  1% to 25% inflammation, 2  25% to 50% inflammation, 3  50% to 75%
inflammation, and 4  75% to 100% inflammation. Blank MPs, empty Ace-DEX microparticles; AR-12/MPs, Ace-DEX MPs encapsulating AR-12; Gent,
gentamicin.
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macrophage targeting and hydrophobicity mitigation allowed for
AR-12/MPs to be superior to free AR-12 when delivered via the
same route of infection in vivo (Fig. 4 and 5). Regardless of the
route of infection, F. tularensis primarily enters phagocytic cells,
which facilitates systemic dissemination of the pathogen through-
out the body, including the lungs, liver, and spleen.When AR-12/
MPs were given through the same route as that used for infection,
it is likely that the AR-12/MPs were efficiently taken up by both
infected and noninfected phagocytic cells, resulting in higher local
intracellular concentrations than those of the free drug. In addi-
tion, the AR-12/MP-containing noninfected cells would be ex-
pected to be more resistant to phagocytosed Francisella. Interest-
ingly, we observed that i.n. delivery of AR-12/MPs to treat i.n.
infected mice resulted in stronger effects than those for i.p. AR-
12/MP delivery to treat i.p. infected mice (Fig. 4 and 5). This may
reflect higher local concentrations of AR-12 as a result of delivery
to a more confined compartment in the lung. Additionally, the
respiratory tract is a major portal of entry for pneumonic tulare-
mia, from which dissemination occurs (1). The delivery of F. tu-
larensis as a bioweapon by this route is particularly dangerous due
to the ease of infectivity and the high fatality rate from infection
(1). In the case of a bioterrorism attack, needle-free routes are
preferred, since they allow for enhanced patient compliance, de-
creased injection site pain, reduced costs, and administration of
the anti-infective at the site of action (43). Due to all of these
factors, i.n. delivery of AR-12/MPs would be beneficial during a
bioterror threat.
Use of i.n. delivery of AR-12/MPs at days 0 and 1 to treat i.n.
infection with F. tularensis resulted in a prolonged survival time
(Fig. 5) and better control of bacterial burdens in the lungs and
spleen (Fig. 7). AR-12/MPs alone could even protect the infected
mice from death when the treatment was extended to 3 days (days
0, 1, and 2 postinfection) (Fig. 8A). This was possibly due to the
observed increase in inflammation at 3 to 6 days postinfection,
whereby phagocytic cells were shown to be recruited to the lungs
of AR-12/MP-treated mice (Fig. 3 and 6). This inflammation, to-
gether with autophagy induced by AR-12/MPs, may overcome
early immune suppression by F. tularensis in the lungs (15, 44),
enhancing control of the pathogen by the host. Indeed, the CFU
data together with the lung histopathology data indicate that in-
FIG 7 Bacterial burdens in the lungs and spleens of mice (n 5) infected i.n. with 10 CFU of F. tularensis and then treated i.n. with 1.5 mg/kg of AR-12/MPs on
days 0 and 1 postinfection, with or without a suboptimal dose (0.5mg/kg) of daily gentamicin (Gent) given for the duration of the experiment. Bacterial burdens
were examined at 3, 6, and 9 days postinfection (DPI). *, P 0.05; **, P 0.01. All other comparisons described in Results did not reach these levels of statistical
significance.
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flammation induced byAR-12/MPs helps infectedmice to control
the bacterial burden in the lungs.
When AR-12 and AR-12/MPs were delivered in combination
with suboptimal gentamicin treatment, mice infected with F. tu-
larensis had prolonged survival over that with either drug alone
(Fig. 4, 5, and 7). Additionally, using an increased duration of
dosing with AR-12/MPs and suboptimal gentamicin led to de-
creased bacterial burdens with respect to all other groups. Com-
bination therapeutic strategies consisting of host-directed agents
and traditional antibiotics are an emerging approach to control
intracellular bacterial infections (45). This approachmay lead not
only to increased effectiveness of antibiotics but also to reduced
antibiotic usage and reduced development of resistant strains. In
fact, i.n. delivery of interleukin-12 (IL-12) in combination with
antibiotics has shown efficacy in the control of F. tularensis infec-
tion in a mouse model (13). Directly related to our study, Lo et al.
(46) showed that AR-12 could be used to sensitize the intracellular
bacterial pathogen Salmonella enterica serovar Typhimurium to
FIG 8 (A) Survival curves for BALB/cmice (n 5) infected i.n. with 10 CFU of F. tularensis. The infectedmice were given 0.75mg/kg of AR-12 inmicroparticles
(AR-12/MPs) i.n. on days 0, 1, and 2 postinfection. As indicated, gentamicin (Gent) was given i.p. daily at 0.5mg/kg. * and ** indicate statistical significance with
respect to the blank MP group (*, P  0.05; **, P  0.01). (B) Bacterial burdens in the lungs and spleens of infected mice (n  4) examined at 3 and 6 days
postinfection (DPI).
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traditional antibiotics both in vitro and in vivo, highlighting the
possible use of AR-12 as a host-directed therapy.
In this study, we showed that the host-directed therapeutic
AR-12 encapsulated in Ace-DEX microparticles has the ability to
control F. tularensis in vitro and in vivo. In addition to having
lower toxicity, the encapsulated form of AR-12 showed greater
efficacy in vivo than did free AR-12.When the dosing regimenwas
expanded to 3 days, survival ofmice infected with F. tularensiswas
enhanced, and codelivery of AR-12 with a suboptimal dose of
gentamicin enhanced the protective effects in a mouse model of
tularemia over those with either drug alone by reducing bacterial
loads in the lungs and spleen. Thus, combination therapy using a
host-directed agent can aid in pathogen clearance and is a prom-
ising future direction of research. Taken together, the data in our
study provide support for the potential use of Ace-DEX-encapsu-
lated AR-12 for the treatment of pneumonic tularemia.
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